News | May 16, 2025
JB Pharma records revenue growth of 10% to Rs. 949 crore in Q4 FY25
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
Ideal for extreme dry skin and hyperkeratotic conditions such as psoriasis and ichthyosis, Ureaderm offers the next step in evidence-based, effective skin hydration
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
EBITDA before special items decreases to €4.08 billion (7.4%)
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices
Scores highest PAT of Rs. 118 crore in FY25
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
Subscribe To Our Newsletter & Stay Updated
